Study: Half of people on statins don't hit healthy cholesterol levels

After two years of treatment with statins, about half of patients in primary care still don't hit healthy cholesterol levels.
Source: Health News - - Category: Consumer Health News Source Type: news

Related Links:

Conclusions Decrease in cholesterol efflux, increase in uptake, and excess esterification of cholesterol compounded by the action of lipid peroxidation products generated by inflammatory processes contribute to foam cell formation in atherosclerosis. Since these are critical events in the pathogenesis of atherosclerosis, they have been extensively studied. On the contrary, although a role for host lipid metabolism in mycobacterial pathogenesis has been established, research in the different components that contribute to the alteration in host lipid metabolism and cholesterol homeostasis is still in the nascent stages. The...
Source: Frontiers in cellular and infection microbiology - Category: Microbiology Source Type: research
Authors: Dolara A Abstract Deprescribing is a holistic process to identify medications that can be ceased, substituted or reduced. This process can improve the health of older patients and also enhance their compliance to the prescribed medications which are actually beneficial. Recommendations and guidelines have been elaborated for extensively prescribed drugs. In clinical cardiology the process of deprescribing is a challenge for doctors because of withdrawal-related adverse effects, but it may be applied in certain clinical conditions such as the discontinuation of statin prescription in patients with advanced ...
Source: Acta Cardiologica - Category: Cardiology Tags: Acta Cardiol Source Type: research
Giuseppe Ristagno1*, Francesca Fumagalli1, Barbara Bottazzi2, Alberto Mantovani2,3,4, Davide Olivari1, Deborah Novelli1 and Roberto Latini1 1Department of Cardiovascular Research, Mario Negri Institute for Pharmacological Research IRCCS, Milan, Italy 2Humanitas Clinical and Research Center-IRCCS, Milan, Italy 3Humanitas University, Milan, Italy 4The William Harvey Research Institute, Queen Mary University of London, London, United Kingdom The long pentraxin PTX3 is a member of the pentraxin family produced locally by stromal and myeloid cells in response to proinflammatory signals and microbial moieties. The p...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
AbstractPurpose of ReviewThe primary purpose of this article was to review the next-generation lipid-lowering therapies that are under current development and clinical testing. We reviewed the mechanism of action of these drugs and how they act on different pathways of lipid metabolism. Additionally, we aimed to present data from clinical trials evaluating clinical outcomes, efficacy, and safety of these novel agents. Lastly, we sought to provide recommendations for clinical practice and to comment on the cost-benefit analyses of such drugs.Recent FindingsWe evaluated the following lipid-lowering agents as they pertain to ...
Source: Current Cardiovascular Risk Reports - Category: Cardiology Source Type: research
Assessing the relationship between statin use and oncologic outcomes among men electing active surveillance for localized prostate cancer, Published online: 17 April 2019; doi:10.1038/s41391-019-0147-0Assessing the relationship between statin use and oncologic outcomes among men electing active surveillance for localized prostate cancer
Source: Prostate Cancer and Prostatic Diseases - Category: Urology & Nephrology Authors: Source Type: research
Conclusion Figure 4 shows that the 27 different molecular defects within the ALB so far reported to cause CAA are located in ten different exons (1, 3, 4, 5, 7, 8, 9, 10, 11, and 12) and in seven different introns (1, 2, 3, 6, 10, 11, and 12) (The Albumin Website, 2018; Caridi et al., 2019). Variations in the last two coding exons (13 and 14) would probably cause the presence of a circulating C-terminal variant of the protein and not CAA. The first twelve exons of ALB, with the exception of the two shortest, exons 2 and 6, were reported to contain at least one molecular defect resulting in CAA (The Albumin Website, 2018; ...
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
Conditions:   Kawasaki Disease;   Coronary Artery Abnormalities Intervention:   Sponsor:   Children's Hospital of Fudan University Not yet recruiting
Source: - Category: Research Source Type: clinical trials
A study of more than 165,000 people suggests that fewer than half of those who start taking statins reach cholesterol targets within two years
Source: New Scientist - Health - Category: Consumer Health News Source Type: research
Over half of patients started on statin therapy do not achieve optimal therapeutic reduction of their cholesterol within two years, a study published in Heart has found.
Source: The Pharmaceutical Journal - Category: Drugs & Pharmacology Source Type: research
TUESDAY, April 16, 2019 -- More than half of patients initiating statin therapy have a suboptimal low-density lipoprotein cholesterol (LDL-C) response within 24 months, according to a study published online April 15 in Heart. Ralph Kwame Akyea,...
Source: - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Cholesterol | Health | Primary Care | Statin Therapy | Study